GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

The deal, originally announced in January this year, enables Boston Scientific’s entry into sacral neuromodulation (SNM), a high-growth adjacency for its Urology business. The company paid $71 ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific currently looks forward to completing the previously announced acquisition of Axonics in the second half of 2024. Within Neuromodulation, Boston Scientific’s pain business is ...

The company primarily operates through its MedSurg (endoscopy, urology, and neuromodulation ... a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp ...

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...